Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04698031 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorCompletion pushed from Jul 1, 2026 to Dec 1, 2026Study description expanded, about 8 words · Eligibility criteria shortened, about 1 wordv16Show 2 more changesShow less
MinorTrial status: Recruiting to Active, Not RecruitingEnrollment target: estimated 125 to confirmed 134 · Primary completion date: Apr 1, 2026 to May 1, 2026 · Completion date: May 30, 2026 to Jul 1, 2026 · 1 morev15Show 4 more changesShow less
Enrollment target: estimated 125 to confirmed 134
Primary completion date: Apr 1, 2026 to May 1, 2026
Completion date: May 30, 2026 to Jul 1, 2026
Site details revised
NotablePrimary completion date: Apr 30, 2025 to Apr 1, 2026Enrollment target: 152 to 125 · Completion date: May 30, 2025 to May 30, 2026v14Show 2 more changesShow less
MinorPrimary completion date: Mar 31, 2025 to Apr 30, 2025Completion date: Apr 30, 2025 to May 30, 2025 · Site details revised · Eligibility criteria expanded, about 1 wordv12Show 3 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStart date changed from estimate of Mar 1, 2022 to Mar 30, 2022 · Site details revisedv11Show 2 more changesShow less
Start date changed from estimate of Mar 1, 2022 to Mar 30, 2022
Site details revised
MinorStart date: Jan 31, 2022 to Mar 1, 2022v10
NotableStart date: Nov 30, 2021 to Jan 31, 2022Primary completion date: Feb 28, 2025 to Mar 31, 2025v9Show 1 more changeShow less
Primary completion date: Feb 28, 2025 to Mar 31, 2025
NotableStart date: Oct 20, 2021 to Nov 30, 2021v8
MinorStart date: Sep 30, 2021 to Oct 20, 2021v7
NotableStart date: Jul 30, 2021 to Sep 30, 2021Primary completion date: Jan 31, 2025 to Feb 28, 2025 · Completion date: Feb 28, 2025 to Apr 30, 2025v6Show 2 more changesShow less
Primary completion date: Jan 31, 2025 to Feb 28, 2025
Completion date: Feb 28, 2025 to Apr 30, 2025
NotableStart date: Jun 18, 2021 to Jul 30, 2021v5
NotableStart date: May 1, 2021 to Jun 18, 2021v4
NotableStart date: Apr 1, 2021 to May 1, 2021v3
NotableStart date: Feb 1, 2021 to Apr 1, 2021Primary completion date: Nov 29, 2024 to Jan 31, 2025 · Completion date: Dec 31, 2024 to Feb 28, 2025v2Show 2 more changesShow less
Primary completion date: Nov 29, 2024 to Jan 31, 2025
Completion date: Dec 31, 2024 to Feb 28, 2025
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient ischemic attack. SBIs are linked to a significant increase in risk for subsequent stroke and cognitive decline. However, no biomarker is currently available that can predict the recurrence of these subclinical lesions. Coated-platelets are a measure of platelet procoagulant potential significantly increased in patients with ischemic stroke or transient ischemic attack compared to unaffected controls. Higher coated-platelet levels are strongly associated with both the presence and number of SBIs. Among medications approved for preventing stroke recurrence, the investigators identified clopidogrel as a pharmacological agent leading to a decrease in coated-platelet levels. In this project, the investigators plan to evaluate if clopidogrel can decrease the rate of occurrence of new silent brain infarctions. The result will enhance the investigators understanding of the relationship between platelets and silent brain infarcts, leading to improved health care delivery and also potential targets for novel preventive pharmacological interventions.